EYPT - EyePoint Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.7275
+0.0060 (+0.83%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.7215
Open0.7300
Bid0.7161 x 2200
Ask0.7450 x 800
Day's Range0.7100 - 0.7450
52 Week Range0.7000 - 2.6900
Volume448,426
Avg. Volume887,656
Market Cap90.75M
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • GlobeNewswire

    EyePoint Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

    WATERTOWN, Mass., May 26, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.

  • GlobeNewswire

    EyePoint Pharmaceuticals Presents Data Showcasing DEXYCU® at the American Society of Cataract and Refractive Surgery 2020 Virtual Annual Meeting

    EyePoint Pharmaceuticals, Inc. (EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of positive retrospective case study data supporting DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery. The data were presented in three electronic posters and one oral paper session at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting on May 16-17, 2020. The ongoing retrospective study is designed to provide large-scale, real-world data from surgeons based on their early experiences with DEXYCU.

  • GlobeNewswire

    EyePoint Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments

    - Total revenues of $7.5 million and net product revenues of $4.7 million - - Cash conservation and reorganization initiatives coupled with recent financings.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces First Quarter 2020 Financial Results Release Date and Conference Call Information

    WATERTOWN, Mass., April 29, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.

  • GlobeNewswire

    EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update

    EyePoint Pharmaceuticals, Inc. (EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has taken proactive measures in response to changing market conditions caused by the novel coronavirus (COVID-19) global pandemic. EyePoint is committed to providing uninterrupted access to our products during the COVID-19 pandemic for those patients who are in essential need of treatment.

  • GlobeNewswire

    EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress

    – Total revenues of $8.6 million in Q4 2019 and $20.4 million for full year 2019 – – Net product revenues of $7.9 million in Q4 2019 and $16.8 million for full year 2019 –.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ®

    EyePoint Pharmaceuticals, Inc. (EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced positive topline 36-month follow-up data from the second Phase 3 trial of YUTIQ®(fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces Fourth Quarter and Full-Year 2019 Financial Results Release Date and Conference Call Information

    WATERTOWN, Mass., Feb. 27, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    EyePoint Pharmaceuticals, Inc. (EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $1.45 per share. The gross proceeds of the offering to the Company are expected to be approximately $21,750,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, EyePoint granted the underwriters a thirty-day option to purchase up to an additional 2,250,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

    EyePoint Pharmaceuticals, Inc. (EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire

    EyePoint Pharmaceuticals and Vision Center Network of America Sign Purchase Agreement for DEXYCU®

    EyePoint Pharmaceuticals, Inc. (EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Vision Center Network of America, LLC (“VCNA”), a Clinically Integrated Network (“CIN”) with the aim of significantly improving the healthcare delivery system in the specialty area of ophthalmic surgery, today announced that they have entered into an purchase agreement for DEXYCU® (dexamethasone intraocular suspension) 9% for its network of nine surgery centers located in New York and New Jersey that perform an estimated 60,000 cataract procedures annually. The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.

  • GlobeNewswire

    EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion

    EyePoint Pharmaceuticals, Inc. (EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has signed an exclusive license agreement with Equinox Science, LLC, to develop vorolanib, a tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration (wAMD), diabetic retinopathy (DR) and retinal vein occlusion (RVO). Vorolanib is being developed as EYP-1901 utilizing Eyepoint’s bioerodible Durasert technology, a miniaturized, injectable, sustained-release intravitreal drug delivery system with a 6-month duration.

  • GlobeNewswire

    EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan

    EyePoint Pharmaceuticals, Inc. (EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a fast-growing ophthalmology focused pharmaceutical company in China, today announced an exclusive license agreement for the development and commercialization of DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in Mainland China, Hong Kong, Macau and Taiwan. DEXYCU is currently marketed by EyePoint in the U.S. EyePoint maintains worldwide development and commercialization rights outside of the territories licensed to Ocumension.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues

    For the fourth quarter ended December 31, 2019, total revenues are estimated to be between $7.5 and $8.2 million and net product revenues are estimated to be between $6.9 and $7.6 million, a significant acceleration from net product revenues of $1.0 million reported for the third quarter ended September 30, 2019. For the full-year 2019, total revenues are estimated to be between $19.3 and $20.0 million and net product revenues are estimated to be between $15.8 and $16.5 million.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU® Within One of the Largest Integrated Delivery Systems in the U.S.

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has entered into a formal two-year contract with one of the largest integrated delivery systems in the U.S. to offer DEXYCU® within its network. This agreement opens up new distribution channels for DEXYCU that were previously unavailable in key U.S. regions, including California, Washington, Georgia, Colorado and mid-Atlantic states. EyePoint has also received Preferred Vendor status from the system.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced an amendment to its existing debt facility with CRG Servicing LLC (CRG). Under the terms of the amendment, CRG has waived the financial covenant associated with the Company’s product revenue of DEXYCU® and YUTIQ® for the twelve-month period ending on December 31, 2019. “CRG shares our vision of expanding the reach of DEXYCU® and YUTIQ® across the U.S. on behalf of patients suffering from ocular diseases who have few alternative therapies available,” said George Elston, Chief Financial Officer and Head of Corporate Development of EyePoint Pharmaceuticals.

  • GlobeNewswire

    EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development. Mr. Elston has previously been a consultant to the Company and will now transition into this permanent role effective immediately. In this role, Mr. Elston will lead the Company’s financial, capital markets, and corporate development initiatives.

  • GlobeNewswire

    EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress

    – U.S. commercial launch trajectory for DEXYCU® and YUTIQ® gains momentum with strong customer order growth over Q2 – – DEXYCU customer orders increased 207% over Q2 with.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has signed an interim agreement with the U.S. Department of Veteran Affairs (VA) for DEXYCU® and YUTIQ® to be included on the Federal Supply Schedule (FSS), providing U.S. veterans and other federal government agencies with access to both products. The VA FSS contract will extend access to Eyepoint products to over nine million VA beneficiaries and others within the federal system. The final VA contract is expected to be executed in the next few months and have a five-year term.

  • GlobeNewswire

    EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®

    DEXYCU to be available to diverse member network of Vizient, the largest GPO in the U.S. WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a formal three-year contract with Vizient Inc. effective today, November 1, 2019, to offer DEXYCU® with enhanced savings to Vizient’s diverse membership, which includes  more than 50% of the nation’s acute care providers, including 95% of the nation’s academic medical centers, and more than 20% of ambulatory care providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $100 billion in annual purchasing volume, to improve patient outcomes and lower costs.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter ended September 30, 2019 on Thursday, November 7. A live webcast will be available on the Investor Relations section of the corporate website at http://www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced today that the Company’s permanent and specific J-Code for YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye is now in effect. “Uveitis specialists, insurers and patients now stand to benefit from a more streamlined, efficient and permanent reimbursement process with the addition of our new YUTIQ-specific J-Code,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “This milestone is particularly important as J-Codes are utilized by CMS and commercial insurers, and the early issuance allows for our best-in-class approval and reimbursement process to be in effect sooner than we had previously anticipated.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

    WATERTOWN, Mass., Sept. 27, 2019 -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • GlobeNewswire

    EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    WATERTOWN, Mass., Sept. 26, 2019 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • GlobeNewswire

    EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting

    WATERTOWN, Mass., Sept. 09, 2019 -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.